Abstract Disclosed is a method for measuring the effectiveness of therapy intended to kill malignant cells in vivo in a mammal, comprising the steps of obtaining monoclonal antibody that is specific to an internal cellular component of the mammal but not to external cellular components, wherein the monoclonal antibody is labeled; contacting the labeled antibody with tissue of a mammal that has received therapy to kill malignant cells in vivo, and determining the effectiveness of the therapy by measuring the binding of the labeled antibody to the internal cellular component. The internal cellular component is preferably insoluble intracellular antigen, and the label is preferably a radionuclide, a radiopaque material, or a magnetic resonance-enhancing material. Also disclosed is a method whereby the antibody to insoluble intracellular antigen is conjugated to an antineoplastic agent, so that upon administration of the antibody-antineoplastic agent conjugate, antineoplastic agent may be delivered to the tumor. Also disclosed are antibodies for use with the foregoing methods.
A method for measuring the effectiveness of therapy intended to kill malignant cells in vivo in a mammal, comprising the steps of: obtaining monoclonal antibody that is specific to an insoluble internal cellular component of cell ghosts of both normal and malignant cells of said mammal but not to external cellular components, said monoclonal antibody being labeled; contacting said labeled antibody with tissue of a mammal that has received therapy to kill malignant cells in vivo, thereby permitting said antibody to bind preferentially to said insoluble internal cellular component of said cell ghosts of cells that have been killed by said therapy; and determining the effectiveness of said therapy by measuring the binding of said labeled antibody to said insoluble internal cellular component of said cell ghosts of cells killed by said therapy.
Claim 2
Independent Claim
133 words
A method for measuring the effectiveness of therapy intended to kill malignant cells in vivo in a mammal, comprising the steps of: obtaining monoclonal antibody that is specific to an insoluble internal cellular component of cell ghosts of both normal and malignant cells of said mammal but not to external cellular components, said monoclonal antibody being labeled; contacting said labeled antibody with tissue of a mammal that has received therapy to kill malignant cells in vivo, thereby permitting said antibody to bind preferentially to said insoluble internal cellular component of said cell ghosts of cells that have been killed by said therapy; and determining the effectiveness of said therapy by measuring the binding of said labeled antibody to said insoluble internal cellular component of said cell ghosts of cells killed by said therapy.
Claim 3
Dependent Claim
14 words
The method of claim 1, wherein said antibody is to an insoluble intracellular antigen.
Claim 4
Dependent Claim
19 words
The method of claim 2, wherein said contacting step comprises administering said labeled antibody to said mammal in vivo.
Claim 5
Dependent Claim
11 words
The method of claim 3, wherein said label is a radionuclide.
Claim 6
Dependent Claim
12 words
The method of claim 3, wherein said label is a radiopaque material.
Claim 7
Dependent Claim
24 words
The method of claim 3, wherein the binding of said labeled antibody to said insoluble antigen is measured by imaging said label in vivo.
Claim 8
Dependent Claim
11 words
The method of claim 6, wherein said imaging is scintigraphic imaging.
Claim 9
Dependent Claim
11 words
The method of claim 6, wherein said imaging is radiographic imaging.